TABLE 1.

HIV-1 genotype and clinical characteristics of HLA-A2-positive subjects

Patient	Current ARVa	Previous PI historyb	Mutationc	VLd	CD4e	Nadir CD4
2081	LPV/RTV, 3TC, ZDV, TFV		K201, L33L/F, M36M/1, A71V, 184V, L90M	356	310	65
3011	NFV, SQV, d4T	RTV, NFV, SQV	M36I/M/V, 1541/V, A71A/V, G73S, I84I/V, L90M	3,584	237	50
3012	IDV, RTV, 3TC/ZDV, ABC	SQV	M46I, 154V, A71V, V77I, V82A, L90M	8,267	425	110
3013	IDV, 3TC, d4T, EFV		L10I/L, M461	40,611	285	177
3023	RTV, APV, d4T, EFV	RTV, SQV	L10I, M36I, M46L, I54V, V82A, 184V	158,576	395	240
3037	RTV, SQV, ABC		L10I, G48V, A71T/I, V82A, L90M	2,222	420	172
3040	LPV/RTV, d4T, 3TC	IDV, RTV, LPV	L10I, M46I, G48V, V82A, L90M	500	296	96
3043	IDV, 3TC, d4T.	SQV	M46I, A71T/A, N88D, L90M/L	1,982	239	84
3050	LPV/RTV, 3TC, d4T, NVP	SQV, NFN	K20R, M36I, I54V, V82A	7,511	203	9
3057	IDV, d4T, 3TC		L10I, M461, A71T, N88S, L90M/L	500	416	143
3084	d4T, ABC, NVP	IDV, RTV	V32I, M46I, A71V, V82A/V	5,351	411	193
3088	LPV/RTV, d4T, ABC	IDV, SQV, NFV	L10I, K20R, L24I, M36I, M46I, 147I/V, F53L, 154V, V82A	21,637	44	37
3151	RTV, APV, d4T, ddI, 3TC, EFV	SQV, IDV, RTV, APV	I54M, A71V, I84V, L90M	79,800	271	50
3153	RTV, APV, d4T, ddI, 3TC	SQV, IDV, RTV, APV	L10I, M46I, I54I/L, I84V, L90M	2,500	466	198
3156	NFV, ABC, 3TC	RTV, IDV, NFV	L10I, M36I/M/L, I54I/V, A71T/A, 184V, N88N/S	160,750	766	599

^aARV, antiretroviral therapy.

^bLPV/RTV, lopinavir-ritonavir; 3TC, lamivudine; ZDV, zidovudine; TFV, tenofovir; NFV, nelfinavir; SQV, saquinavir; d4T, stavudine; IDV, indinavir; RTV, ritonavir; APV, amprenavir; ddI, didanosine; EFV, efavirenz; ABC, abacavir; NVP, nevirapine.

^cMutations in the protease gene associated with reduced susceptibility to PIs (15). The presence of detectable heterogeneity within the viral sequence population is indicated. e.g., L33L/F points out the presence of both a leucine (L) and phenylalanine (F) at position 33.

^dVL, viral load (copies per milliliter) at time of study.

^eCD4⁺ cell count (cells per cubic millimeter) at time of study.